Summary: Various meta-analytical approaches have been applied to evaluate putative surrogate endpoints (S) of primary clinical endpoints (T), however a systematic assessment of their performance is lacking. Existing methods in the meta-analytic framework can be grouped into two types -conventional and model-based trial-level surrogacy (TLS) measures. Conventional TLS assess the association between treatment effects on S and T, including correlation coefficients and Rsquare measures from weighted linear regression. Model-based TLS included Copula R 2 proposed
Introduction
The evaluation and validation of putative surrogate endpoints in clinical trials is a highly relevant, and controversial topic in methodological and applied statistics. More than a dozen different statistical surrogacy evaluation methods (Weir and Walley, 2006) and numerous publications (Lassere, 2008) have appeared since Prentice (1989) published his milestone paper which laid out the foundation for the validation of putative surrogate endpoint.
However, due to the challenges arising from the methodology and commonly encountered data limitations, no single approach to the assessment of potential surrogate endpoint has been fully accepted across statisticians, clinical trialists, and regulatory authorities.
In recent years, surrogacy evaluation based on multiple trials, as initiated with a Bayesian random effects meta-analysis proposed by Daniels and Hughes (1997) , has increasingly become the preferred method. In 1998, Buyse and Molenberghs (1998) were the first to formulate surrogacy estimates at both the patient and the trial level based on single trial data. Two years later, this paradigm evolved into meta-analytic framework (Buyse et al., 2000) . The shift from assessing surrogacy only at the patient level (usually within a singletrial setting) to assessment at both patient level, and more-importantly at the trial level (Molenberghs et al., 2002) has resulted in a broadly accepted requirement for a surrogate endpoint: the treatment effect observed on a valid surrogate endpoint (substitute) should reliable and precisely predict the treatment effect on the primary endpoint (Biomarkers Definitions Working Group, 2001) . Such two-level surrogacy measures based on meta-analytic procedures have been investigated for various types of endpoints (Burzykowski et al., 2005) .
The Copula R 2 trial proposed by Burzykowski et al. (2001) is perhaps the most popular trial level surrogacy measures in cancer clinical trials when both endpoints are survival outcomes. Shi and Sargent (2009) summarized applications evaluating potential surrogate endpoints in colorectal, prostate, and breast cancer.
Within the meta-analytic framework, there remain several proposed trial-level surrogacy measures which are less mathematically sophisticated but more clinically intuitive. These correlation and coefficient of determination type surrogacy measures have been utilized in the research of Adjuvant Colon Cancer Endpoints (ACCENT) Group and other individual investigators (Shi and Sargent, 2009 ). The ACCENT group has assembled individual patient data from large randomized phase III clinical trials in adjuvant colon cancer conducted worldwide. Their work led to the acceptance of disease-free survival (DFS) as a surrogate endpoint for overall survival (OS) for fluorouracil-based regimens in adjuvant colon cancer studies by United States Food and Drug Administration (FDA) (Sargent et al., 2005 (Sargent et al., , 2007 .
In Sargent et al. (2005) 's work, surrogacy of DFS was evaluated not only based on Copular R 2 trial , but also by the simple measures based on regression or correlation type of analysis.
The broad agreement across these measures strengthened the evidence of DFS as a surrogate for OS in the adjuvant colon cancer settings (Green et al., 2008) . We will refer to these simple methods as conventional approaches, and the Copula R 2 trial , which is based on joint modeling, as a model-based approach from this point forward.
Both the conventional and the model-based trial level surrogacy measures quantify the ability to predict the treatment effect on true endpoint based on observed treatment effect on the surrogate endpoint through hierarchical estimating procedures, i.e. by first estimating the treatment effects on both endpoints within each trial, then performing regression analyses or random effect modeling using the estimated treatment effects across trials. However, a key difference between two approaches is that the surrogate and true endpoints are jointly modeled in a structure of bivariate distribution at the individual patient level for modelbased measures, whereas the estimation procedures of conventional measures ignores the generic correlations between endpoints on the same patient. Estimating both level surrogacy simultaneously introduces computational challenges. In practice, the computational burden of the model-based approaches has been a barrier for the investigators to apply the method.
If simple regression-based approaches could provide good performance with available standard functions or procedures in the statistical software this could have important practical advantages.
The performance of both existing model-based and conventional surrogacy metrics is likely affected by many trial characteristics. It is presently unknown whether the commonlyused measures of surrogacy can provide reliable and unbiased estimates regardless of the magnitude of the true surrogacy of a candidate endpoint. The effective amount of information provided by the data -as determined by the number of trials, trial sizes, and percentage of complete observations -is also likely to affect the surrogacy estimation, but the relative influence of these factors remains poorly understood. Other factors likely to influence surrogate evaluation include the range and location of within-trial treatment effects and the adequacy of distributional assumptions.
In order to address these various issues, we performed a large-scale simulation study to evaluate the estimation performance of the trial level surrogacy measures under a variety scenarios, and to compare the conventional marginal and model-based bivariate surrogacy measures. This work is directly motivated by an ongoing collaboration in colon cancer, the previously mentioned ACCENT group, using data from 18 randomized trials including 20,898 patients. The data set used includes trials from 1977 -1999, and included only trials using flourouracil-based regimens (that was the only effective agent at the time when trials were conducted).
From 1997 to 2002, six new large colon cancer trials were conducted, of which four used new agents in addition to flourouracil. This data is now available. The critical issue of whether DFS remains a valid surrogate endpoint for OS in the presence of these new agents and for more contemporary patients is highly relevant for ongoing drug development. As the ACCENT group endeavored to explore the surrogacy assessment for limited number of new trials with a smaller range of treatment effects, a large-scale simulation-based comparative evaluation of popular surrogacy measure under less-than-ideal scenarios became necessary and important.
The remainder of this article is as follows. We review each of the trial level surrogacy measures for the time-to-event endpoints in Section 2. In Section 3, we introduce a two-stage data generation procedure used to create the multi-trial datasets. Numerical results of the simulation study are reported in Section 4, and head-to-head comparison between an analysis of the new trials in ACCENT database and a simulation with scenario similar are given in Section 5. Discussion and final remarks are given in Section 6, along with further challenges and technical issues of evaluating potential surrogate endpoint and motivation for creation of a simulation engine for testing surrogate endpoint evaluation methods.
Measures of Trial-level Surrogacy

Surrogate endpoints in Oncology
In oncology, overall survival has been widely used as the primary outcome to evaluate novel agents, and is often considered as the "true" endpoint, as it is clearly defined, simple to measure, and easy to interpret. However, in early stage disease settings, extended patient follow-up is required to observe a sufficient number of deaths to achieve the desired statistical power to demonstrate the treatment effect. In addition, the treatment effect measured on OS might be contaminated by the impact of active second line therapies. Considerable interest lies in replacing OS with an earlier endpoint, such as time to recurrence (TTR) or diseasefree survival (DFS) in early disease settings or progression-free survival (PFS) in advanced disease settings. These outcomes have been investigated as potential surrogate endpoints in many oncology applications (Shi and Sargent, 2009) . Here, we focus on the scenario that the both true and surrogate endpoints are time-to-event endpoints, as is typically the case in cancer clinical trials.
Surrogacy measures under investigation
Before describing each of the surrogacy measures of interest, we first introduce the notation used throughout the article. Suppose there are total of I trials (i = 1, . . . , I) and in the ith trial n i patients (j = 1, . . . , n i ) are enrolled. Let T ij and S ij be the time-to-event variables that denote the true and surrogate endpoints respectively, and let X ij be an indicator variable for treatment, with value of 1 for experimental arm and 0 for control arm. Table 1 summarizes the key features of four trial-level surrogacy measures assessed in the current simulation study. We use the notation R [ Table 1 The other R 2 -type of estimators of the trial-level surrogacy presented in Table 1 In order to produce comparable results, the treatment effects were kept in the regression coefficient form (i.e. ln(HR)) and correlation coefficients were squared to align with coefficients of determination. Standard errors of the three conventional measures were estimated from 1,000 bootstrapped samples per dataset.The standard error for Copula R 2 trial was estimated based on the delta method. Both data generation and surrogacy estimation were performed in R.
Simulations
Two-stage Data Generation
A hierarchical two-stage data generation process was developed to simulate the multi-trial clinical trial datasets. The trial-specific intercepts and treatment effects (slopes) for both S and T were generated from a multivariate normal distribution at the trial level. These simulated coefficients were used to generate the time-to-event S ij and T ij for jth patient in ith trial at the individual patient level, as detailed below.
Let (µ S i , µ T i , α i , β i ) denote the regression coefficient vector for ith trial. This random vector can be simulated from the following multivariate normal (MVN) distribution which is equivalent to the random-effect model described by Buyse et al. (2000) and Burzykowski et al. (2001) ,
where µ S and α (µ T and β) denote the means of intercepts and slopes across all the trials for S (T ). The reduced Copula R 2 trial assumes the prediction of the treatment effect (slope) on T for a new trial based on observed slope on S from the same new trial is independent of random intercepts, and thus can be formulated as R A joint Weibull survival model was constructed to generate the correlation between the uncensored time-to-event S and T for each patient at the individual level. Cowles (2004) showed that a Weibull distribution can be expressed as a scaled mixture of a half-normal distribution (i.e. of standard normal distribution truncated to the positive real line) and an exponential random variable with rate parameter equal to one. Two separate sets of independent exponential random variables are simulated for S and T . When only one set of truncated normal variates are generated to form two time-to-event outcomes, there will be strong correlation between S ij and T ij . When two separate sets of truncated normal variates are used, S ij and T ij will be uncorrelated. This gives two scenarios -strong and weak individual level surrogacy for the generated S. In the scenarios involving censoring, independent and non-informative censorship was assumed. The censoring time was generated by independent uniform distribution and the desired censoring rates controlled by the parameter values of the uniform distribution.
Prior to performing our primary simulations, we conducted pilot simulations to confirm the desired data characteristics were precisely and consistently represented in our generated datasets. The two-stage data generation procedure described above performs well to produce the scenarios considered.
Simulation Settings
Considering TTR as the candidate surrogate endpoint and OS as the true endpoint, levels explored for each factor of interest are listed in table 2, below.
[ Table 2 about here.]
With several trial characteristics above to consider, we assess their relative impact on the estimation performance of the surrogacy measures of interest by holding all other factors fixed at the "best-case scenario" as described by the following: true trial-level surrogacy of R 2 = 0.90, no censoring, 50 trials, 2000 patients per trial, strong patient-level correlation between S and T , and a wide range of hazard ratios covering one. For each scenario, 500 multi-trial datasets were generated, and all four surrogacy measures and their standard errors were computed. Other parameters involved in the data generation were fixed at the values derived from ACCENT database.
Simulation Results
Simulations based on Weibull Data Generation
The results of the simulation assessment according to each of the main factors were presented in Table 3 . Bias and mean squared error (MSE) were calculated to evaluate the accuracy and precision of the surrogacy measures of interest, respectively. Additionally, the coverage of the 95% confidence interval estimates was reported.
Under the best-scenario both model-based and conventional surrogacy measures show sufficient precisions and satisfactory coverage of the 95% confidence intervals. Although a systematic underestimation of the true trial-level surrogacy was observed even in this case, the magnitude of the bias is minor. As each factor was set farther from the level given by the optimal scenario, the estimation performances of all four surrogacy measures decreased [ Table 3 , we see that the range of treatment effects across trials has a severe negative impact on trial-level surrogacy estimation; specifically, the coverage of 95% confidence intervals becomes extremely low when the range of the treatment effects is small, while bias and MSE increase dramatically. Furthermore, this negative impact is worst for Copula R the patient-level correlation between S and T has only a slight effect on the estimation performance for all four surrogacy measures.
Simulations Based on a Log-normal Data Generation
The estimation of Copula R 2 trial assumes trial and endpoint-specific Weibull baseline hazard functions. The simulation results presented in Section 4.1 were based on data generated from Weibull distributions at the patient level, so it is reasonable to expect that the copula and proportional hazards models used in the first stage of surrogacy estimation provided a good fit to the data. In practice, however, clinically observed time-to-event data may be poorly represented by monotone or proportional hazard functions. Thus, we extend our simulation study to investigate the impact of model misspecification, by generating new trials of data from correlated log-normal distributions. We provide detailed results in Table 4 . We repeat the strategy of holding all other factors fixed at the best case scenario, and focus on estimation performance under variations of true trial-level surrogacy and rate of censoring.
[ Table 4 about here.]
In general, we find that both the conventional and the model-based surrogacy measures are robust to (mildly incorrect) simplifying assumptions regarding the endpoint and trialspecific hazard functions of the patient-level outcomes. It should be noted that the lognormal data in these simulations, similar to the Weibull data in our previous simulations, were generated using parameter estimates from ACCENT. When censoring is introduced, however, we observe that Copula R 2 trial -which continues to assume the patient-level data are marginally distributed as Weibull -becomes sensitive to parametric misspecification.
Specifically, the degree of underestimation becomes severe, while decreased true trial-level R 2 corresponds to significantly decreased coverage. We performed another set of simulations to assess trial-level surrogacy while mimicking characteristics of stage III patients from the 6 new ACCENT trials. In addition to match with trial sizes, censoring rate, and range of the treatment effects, Weibull baseline hazards were assumed for the correlated event times TTR and OS. All other data generation parameters were fixed at estimates from the new ACCENT trials, considering stage III patients only.
In this set of simulations, we consider true trial-level surrogacy equal to 0.90. The results of these simulations are given in Table 5 , as well as the estimates of surrogacy based on the true data from 6 new ACCENT studies.
[ Table 5 However, the large uncertainty illustrated by the extreme wide confidence intervals makes this conclusion less compelling.
Discussion
To the best of our knowledge, this is the first large-scale simulation study to assess and compare trial-level surrogacy measures frequently used in practice. Characteristics of the generated data were chosen to capture key aspects of multi-trial analyses where both candidate surrogate and true outcomes are time-to-event in nature. In addition to true triallevel surrogacy, the number of trials, sample size within trials, censoring rate, range of treatment effects across trials, and patient-level correlation between endpoints were selected as important factors for practical consideration. The data generation process developed here facilitated a systematic approach to our study, in which one or more key factors may be varied in a controlled manner while holding all other factors fixed at ideal settings. Four trial-level surrogacy measures were evaluated in terms of their relative estimation performance and robustness to less-than-ideal trial characteristics one might encounter in practice.
Our simulation study demonstrated that true surrogacy can be estimated accurately and precisely when a large number of large trials are available, rate of censoring is low, and a large range of treatment effects exists. Unfortunately in practice this best-case scenario is unlikely to be encountered. When the degree of departure is moderate when each factor considered separately, the loss of precision and underestimation of surrogacy remain somewhat tolerable.
It should be note that, unfortunately, frequently several of the worst-case settings considered separately here are commonly seen in combination in practice. For example as illustrated in Section 5, the data in hand had a limited number of trials with high censoring rates and a small range of the treatment effects across trials.
Overall , Multiple additional challenges and technical issues exist for evaluating potential surrogate endpoints in real applications. In particular, when only a limited number of trials are available, the estimation variability and low coverage of 95% confidence intervals become a major concern. A common quick fix to this problem involves breaking a trial into sub-units such as centers and estimating the surrogacy on the level of the sub-units rather than the true trials, thereby effectively increasing the meta-analytic sample size. However, the tradeoff between gain of precision and loss of accuracy by splitting trials is not transparent. Further study regarding this situation is ongoing.
Within our current study, the two correlated time-to-event endpoints are assumed to be exchangeable. In many real applications, this many not be the case. For example, DFS is One of the barriers of applying the two-level surrogacy estimation methods is the computation challenge. This encouraged us to develop user friendly software for surrogate endpoint evaluations (available from the first author by request). This is our first step to creating a integrated software suite which can include multiple methods for estimating or evaluating surrogate endpoints. Combined with a sophisticated data generating process, our goal is to create a simulation engine to test and compare existing and newly developed surrogate evaluation methods. Individual-level correlation Weak (correlation near 0), Strong (correlation near 0.70)
Range of hazard ratios across trials Approximate ranges: Large (0.5 to 2.0), Moderate(0.7 to 1.6), Small (0.9 to 1.1) 
